作者
Sang‐Eun Lee,Youngtaek Hong,J.H. Hong,Juyeong Jung,Ji Min Sung,Daniele Andreini,Mouaz H. Al‐Mallah,Matthew J. Budoff,Filippo Cademartiri,Kavitha M. Chinnaiyan,Jung Hyun Choi,Eun Ju Chun,Edoardo Conte,Ilan Gottlieb,Martin Hadamitzky,Yong‐Jin Kim,Byoung Kwon Lee,Jonathon Leipsic,Erica Maffei,Hugo Marques,Pedro de Araújo Gonçalves,Gianluca Pontone,Sanghoon Shin,Peter H. Stone,Habib Samady,Renu Virmani,Jagat Narula,Leslee J. Shaw,Jeroen J. Bax,Fay Y. Lin,James K. Min,Hyuk‐Jae Chang
摘要
Background Radiomics is expected to identify imaging features beyond the human eye. We investigated whether radiomics can identify coronary segments that will develop new atherosclerotic plaques on coronary computed tomography angiography (CCTA). Methods From a prospective multinational registry of patients with serial CCTA studies at ≥ 2-year intervals, segments without identifiable coronary plaque at baseline were selected and radiomic features were extracted. Cox models using clinical risk factors (Model 1), radiomic features (Model 2) and both clinical risk factors and radiomic features (Model 3) were constructed to predict the development of a coronary plaque, defined as total PV ≥ 1 mm3, at follow-up CCTA in each segment. Results In total, 9583 normal coronary segments were identified from 1162 patients (60.3 ± 9.2 years, 55.7% male) and divided 8:2 into training and test sets. At follow-up CCTA, 9.8% of the segments developed new coronary plaque. The predictive power of Models 1 and 2 was not different in both the training and test sets (C-index [95% confidence interval (CI)] of Model 1 vs. Model 2: 0.701 [0.690–0.712] vs. 0.699 [0.0.688–0.710] and 0.696 [0.671–0.725] vs. 0.0.691 [0.667–0.715], respectively, all p > 0.05). The addition of radiomic features to clinical risk factors improved the predictive power of the Cox model in both the training and test sets (C-index [95% CI] of Model 3: 0.772 [0.762–0.781] and 0.767 [0.751–0.787], respectively, all p < 00.0001 compared to Models 1 and 2). Conclusion Radiomic features can improve the identification of segments that would develop new coronary atherosclerotic plaque. Clinical Trial Registration ClinicalTrials.gov NCT0280341.